Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Error in Table

Error in Table In the Original Investigation titled “Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema,” published online November 25, 2015, in JAMA Ophthalmology,1 there was an error in Table 3. The change in CST from baseline, mean (SD), µm for aflibercept (n = 61) should have read as follows: “−285 (147).” This article was corrected online. References 1. Wells JA, Glassman AR, Jampol LM, et al; Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema [published online November 25, 2015]. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2015.4599.PubMedGoogle Scholar http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Error in Table

JAMA Ophthalmology , Volume 134 (4) – Apr 1, 2016

Error in Table

Abstract

In the Original Investigation titled “Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema,” published online November 25, 2015, in JAMA Ophthalmology,1 there was an error in Table 3. The change in CST from baseline, mean (SD), µm for aflibercept (n = 61) should have read as follows: “−285 (147).” This article was corrected online. References 1....
Loading next page...
 
/lp/american-medical-association/error-in-table-0vcH483S7d
Publisher
American Medical Association
Copyright
Copyright © 2016 American Medical Association. All Rights Reserved.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2016.0428
Publisher site
See Article on Publisher Site

Abstract

In the Original Investigation titled “Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema,” published online November 25, 2015, in JAMA Ophthalmology,1 there was an error in Table 3. The change in CST from baseline, mean (SD), µm for aflibercept (n = 61) should have read as follows: “−285 (147).” This article was corrected online. References 1. Wells JA, Glassman AR, Jampol LM, et al; Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema [published online November 25, 2015]. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2015.4599.PubMedGoogle Scholar

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Apr 1, 2016

References